Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors

Progress in Retinal and Eye Research

Volumn 19, Issue 1, 2000, Pages 87-112

  Sugrue, Michael F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; APRACLONIDINE; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; ETHOXZOLAMIDE; LATANOPROST; METHAZOLAMIDE; N DESETHYLDORZOLAMIDE; UNCLASSIFIED DRUG;

AQUEOUS HUMOR; BINDING SITE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; EYE IRRITATION; GLAUCOMA; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; NAUSEA; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STEADY STATE; TASTE AVERSION;

ADMINISTRATION, TOPICAL; ANIMALS; CARBONIC ANHYDRASE INHIBITORS; CLINICAL TRIALS; FORECASTING; GLAUCOMA; HUMANS; SULFONAMIDES; THIAZINES; THIOPHENES;

EID: 0033990833     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1350-9462(99)00006-3     Document Type: Review

References (122)

1. Adamsons I., Clineschmidt C., Polis A., Taylor J., Shedden A., Laibovitz R. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. J. Glaucoma. 7:1998;253-260.
2. Adamsons I.A., Polis A., Ostrov C.S., Boyle J.E. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. J. Glaucoma. 7:1998;395-401.
3. Alward W.L.M. Medical management of glaucoma. N. Eng. J. Med. 339:1998;1298-1307.
4. Arici M.K., Topalkara A., Güler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int. Ophthalmol. 22:1998;37-42.
5. Baldwin J.J., Ponticello G.S., Anderson P.S., Christy M.E., Murcko M.A., Randall W.C., Schwam H., Sugrue M.F., Springer J.P., Gautheron P., Grove J., Mallorga P., Viader M-P., McKeever B.M., Navia M.A. Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J. Med. Chem. 32:1989;2510-2513.
6. Barber B.L., Strahlman E.R., Laibovitz R., Guess H.A., Reines S.A. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology. 104:1997;334-342.
7. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor. Diamox. Am. J. Ophthalmol. 37:1954;13-15.
8. Biollaz J., Munafo A., Buclin T., Gervasoni J-P., Magnin J-L., Jaquet F., Brunner-Ferber F. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur. J. Clin. Pharmacol. 47:1995;453-460.
9. Boriack-Sjodin P.A., Zeitlin S., Chen H., Crenshaw L., Gross S., Dantanarayana A., Delgado P., May J.A., Dean T., Christianson D.W. Structural analysis of inhibitor binding to human carbonic anhydrase II. Protein Sci. 7:1998;2483-2489.
10. Boyle J.E., Ghosh K., Gieser D.K., Adamsons I.A. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 105:1998;1945-1951.
11. Brooks A.M.V., Gillies W.E. The presentation and prognosis of glaucoma in pseudoexfoliation of the lens capsule. Ophthalmology. 95:1988;271-276.
12. Brubaker R.F. Clinical measurements of aqueous dynamics: implications for addressing glaucoma. Current Topics in Membranes. 45:1998;233-284.
13. Centofanti M., Manni G.L., Napoli D., Bucci M.G. Comparative effects on intraocular pressure between systemic and topical carbonic anhydrase inhibitors: a clinical masked, cross-over study. Pharmacol. Res. 35:1997;481-485.
14. Cioffi G.A. Three assumptions: ocular blood flow and glaucoma. J. Glaucoma. 7:1998;299-300.
15. Clineschmidt C.M., Williams R.D., Snyder E., Adamsons I.A. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology. 105:1998;1952-1959.
16. Conroy C.W. Sulfonamides do not reach the retina in therapeutic amounts after topical application to the cornea. J. Ocular Pharmacol. Ther. 13:1997;465-472.
17. Conroy C.W., Schwam H., Maren T.H. The nonenzymatic displacement of the sulfamoyl group from different classes of aromatic compounds by glutathione and cysteine. Drug Metab. Dis. 12:1984;614-618.
18. Cox S.N., Hay E., Bird A.C. Treatment of chronic macular edema with acetazolamide. Arch. Ophthalmol. 106:1988;1190-1195.
19. Dinslage S., McLaren J., Brubaker R. Intraocular pressure in rabbits by telemetry II: effects of animal handling and drugs. Invest. Ophthalmol. Vis. Sci. 39:1998;2485-2489.
20. Donohue E.K., Wilensky J.T. Trusopt, a topical carbonic anhydrase inhibitor. J. Glaucoma. 5:1996;68-74.
21. Durand-Cavagna G., Delort P., Gordon L.R., Peter C.P., Smith R.L. Cross sensitivity reactions among carbonic anhydrase inhibitors in the guinea pig. J. Toxicol. Cut. Ocular Toxicol. 14:1995;63-73.
22. Egan C.A., Hodge D.O., McLaren J.W., Bourne W.M. Effect of dorzolamide on corneal endothelial function in normal human eyes. Invest. Ophthalmol. Vis. Sci. 39:1998;23-29.
23. Epstein D.L., Grant W.M. Carbonic anhydrase inhibitor side effects. Arch. Ophthalmol. 95:1977;1378-1382.
24. Fahrenbach W.H., Bacon D.R., Van Buskirk E.M. Vasoactive drug effects on the uveal vasculature of the rabbit: a corrosion casting study. Invest. Ophthalmol. Vis. Sci. 30:1989;100.
25. Fishman G.A., Gilbert L.D., Fiscella R.G., Kimura A.E., Jampol L.M. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch. Ophthalmol. 107:1989;1445-1452.
26. Flammer J., Orgül S. Optic nerve blood-flow abnormalities in glaucoma. Progress in Retinal and Eye Res. 17:1998;267-289.
27. Foss R.H. Local application of Diamox: an experimental study of its effect on the intraocular pressure. Am. J. Ophthalmol. 39:1955;336-339.
28. Friedland B.R., Maren T.H. The relation between carbonic anhydrase activity and ion transport in elasmobranch and rabbit lens. Exp. Eye Res. 33:1981;545-561.
29. Gillies W.E., Brooks A.M.V. A clinical trial of MK-507, Trusopt, for raised intraocular pressure - the Australian experience. Aust. N. Z. J. Ophthalmol. 24:1996;111-115.
30. Gordon L.R., Bailly Y., Durand-Cavagna G., Delort P., Peter C.P. Preclinical ocular irritation findings with dorzolamide hydrochloride. J. Toxicol. Cut. Ocular Toxicol. 16:1997;9-17.
31. Grant W.M., Trotter R.T. Diamox (acetazoleamide) in treatment of glaucoma. Arch. Ophthalmol. 51:1954;735-739.
32. Green H., Leopold I.H. Effects of locally administered Diamox. Am. J. Ophthalmol. 40:1955;137-139.
33. Groh M.J.M., Michelson G., Groh M.E.M., Gründler A.E.P. Ocular macro- and microcirculation after topical application of clonidine and metipranolol. German J. Ophthalmol. 3:1994;175-178.
34. Grover S., Fishman G.A., Fiscella R.G., Adelman A.E. Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa. Retina. 17:1997;222-231.
35. Grunwald J.E., Zinn H. The acute effect of oral acetazolamide on macular blood flow. Invest. Ophthalmol. Vis. Sci. 33:1992;504-507.
36. Grunwald J.E., Mathur S., DuPont J. Effects of dorzolamide hydrochloride 2% on the retinal circulation. Acta Ophthalmol. Scand. 75:1997;236-238.
37. Gunning F.P., Greve E.L., Bron A.M., Bose J.M., Royer J.G., George J.L., Lesure P., Sirbat D. Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study. Graefe's Arch. Clin. Exp. Ophthalmol. 231:1993;384-388.
38. Hageman G.S., Zhu X.L., Waheed A., Sly W.S. Localization of carbonic anhydrase IV in a specific capillary bed of the human eye. Proc. Natl. Acad. Sci. USA. 88:1991;2716-2720.
39. Harris A., Kagemann L., Cioffi G.A. Assessment of human ocular hemodynamics. Surv. Ophthalmol. 42:1998;509-533.
40. Harris A., Arend O., Arend S., Martin B. Effects of topical dorzolamide on retinal and retrobulbar hemodynamics. Acta Ophthalmol. Scand. 74:1996;569-572.
41. 2 dependence of retinal arterial and capillary blood velocity. Acta Ophthalmol. Scand. 73:1995;421-424.
42. Harris A., Arend O., Kagemann L., Garrett M., Chung H.S., Martin B. Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. J. Ocular Pharmacol. Ther. 15:1999;189-197.
43. Hartenbaum D. The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension. Clin. Ther. 18:1996;460-465.
44. Hasegawa T., Hara K., Hata S. Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab. Dis. 22:1994;377-382.
45. Hasegawa T., Hara K., Kenmochi T., Hata S. In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes. Drug Metab. Dis. 22:1994;916-921.
46. Hauge A., Nicolaysen G., Thoresen M. Acute effects of acetazolamide on cerebral blood flow in man. Acta Physiol. Scand. 117:1983;233-239.
47. Heijl A., Strahlman E., Sverrisson T., Brinchman-Hansen O., Puustjärvi T., Tipping R. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology. 104:1997;137-142.
48. Hutzelmann J., Owens S., Shedden A., Adamsons I., Vargas E. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. Br. J. Ophthalmol. 82:1998;1249-1253.
49. Hutzelmann J.E., Polis A.B., Michael A.J., Adamsons I.A. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Acta Ophthalmol. Scand. 76:1998;717-722.
50. Infeld D.A., O'Shea J.G. Glaucoma: diagnosis and management. Postgrad. Med. J. 74:1998;709-715.
51. Kaminski S., Hommer A., Koyuncu D., Biowski R., Barisani T., Baumgartner I. Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility. Acta Ophthalmol. Scand. 76:1998;78-79.
52. Kitazawa Y., Azuma I., Iwata K., Tsukahara S., Shiose Y., Araie M., Shirato S., Mizogami K., Mishima H., Futa R., Komemushi S. Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose-response study in patients with glaucoma or ocular hypertension. J. Glaucoma. 3:1994;275-279.
53. Konowal A., Morrison J.C., Brown S.V.L., Cooke D.L., Maguire L.J., Verdier D.V., Fraunfelder F.T., Dennis R.F., Epstein R.J. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am. J. Ophthalmol. 127:1999;403-406.
54. Krupin T., Sly W.S., Whyte M.P., Dodgson S.J. Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency. Am. J. Ophthalmol. 99:1985;396-399.
55. Kuang K., Xu M., Koniarek J.P., Fischbarg J. Effects of ambient bicarbonate, phosphate and carbonic anhydrase inhibitors on fluid transport across rabbit corneal endothelium. Exp. Eye Res. 50:1990;487-493.
56. Ladas I.D., Baltatzis S., Panagiotidis D., Zafirakis P., Kokolakis S.N., Theodossiadis G.P. Topical 2.0% dorzolamide vs oral acetazolamide for prevention of intraocular pressure rise after neodymium:YAG laser posterior capsulotomy. Arch. Ophthalmol. 115:1997;1241-1244.
57. Laibovitz R., Strahlman E.R., Barber B.L., Strohmaier K.M. Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J. Glaucoma. 4:1995;306-313.
58. Laibovitz R., Boyle J., Snyder E., Strohmaier K., Adamsons I. Dorzolamide versus pilocarpine as adjunctive therapies to timolol: a comparison of patient preference and impact on daily life. Clin. Ther. 18:1996;821-832.
59. Larsson L-I., Alm A. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide. Arch. Ophthalmol. 116:1998;19-24.
60. Lass J.H., Khosrof S.A., Laurence J.K., Horwitz B., Ghosh K., Adamsons I. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Arch. Ophthalmol. 116:1998;1003-1010.
61. Laurence J., Holder D., Vogel R., Gross R.L., Haik B.G., Karp D.W., Koby M.M., Zimmerman T.J. A double-masked, placebo-controlled evaluation of timolol in a gel vehicle. J. Glaucoma. 2:1993;177-182.
62. Lee P-Y., Podos S.M., Howard-Williams J.R., Severin C.H., Rose A.D., Siegel M.J. Pharmacological testing in the laser-induced monkey glaucoma model. Curr. Eye Res. 4:1985;775-781.
63. Lindskog S. Structure and mechanism of carbonic anhydrase. Pharmacol. Ther. 74:1997;1-20.
64. Lippa E.A., Schuman J.S., Higginbotham E.J., Kass M.A., Weinreb R.N., Skuta G.L., Epstein D.L., Shaw B., Holder D.J., Deasy D.A., Wilensky J.T. MK-507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology. 98:1991;308-313.
65. Lippa E.A., Carlson L-I., Ehinger B., Eriksson L-O., Finnström K., Holmin C., Nilsson S-E.G., Nyman K., Raitta C., Ringvold A., Tarkkanen A., Vegge T., Deasy D., Holder D., Ytteborg J. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch. Ophthalmol. 110:1992;495-499.
66. Maren T.H. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol. Rev. 47:1967;595-781.
67. Maren T.H. Carbonic anhydrase: general perspectives and advances in glaucoma research. Drug Dev. Res. 10:1987;255-276.
68. Maren T.H. The development of topical carbonic anhydrase inhibitors. J. Glaucoma. 4:1995;49-62.
69. Maren T.H., Wynns G.C., Wistrand P.J. Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme. Mol. Pharmacol. 44:1993;901-905.
70. Maren T.H., Conroy C.W., Wynns G.C., Levy N.S. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J. Ocular Pharmacol. Ther. 13:1997;23-30.
71. Maren T.H., Haywood J.R., Chapman S.K., Zimmerman T.J. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest. Ophthalmol. Vis. Sci. 16:1977;730-742.
72. Martinez A., Gonzalez F., Capeans C., Perez R., Sanchez-Salorio M. Dorzolamide effect on ocular blood flow. Invest Ophthalmol. Vis. Sci. 40:1999;1270-1275.
73. Maurice D.M. The location of the fluid pump in the cornea. J. Physiol. 221:1972;43-54.
74. Maus T.L., Larsson L-I., McLaren J.W., Brubaker R.F. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch. Ophthalmol. 115:1997;45-49.
75. McCannel C.A., Heinrich S.R., Brubaker R.F. Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans. Graefe's Arch. Clin. Exp. Ophthalmol. 230:1992;518-520.
76. Percicot C.L., Schnell C.R., Debon C., Hariton C. Continuous intraocular pressure measurement by telemetry in alpha-chymotrypsin-induced glaucoma model in the rabbit: effects of timolol, dorzolamide, and epinephrine. J. Pharmacol. Toxicol. Methods. 36:1996;223-228.
77. Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv. Ophthalmol. 42:1997;137-151.
78. Ponticello G.S., Sugrue M.F., Plazonnet B., Durand-Cavagna G. Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Borchardt, et al. Integration of Pharmaceutical Discovery and Development: Case Studies. 1998;555-574 Plenum Press, New York.
79. Quigley H.A. Open-angle glaucoma. N. Eng. J. Med. 328:1993;1097-1106.
80. Quigley H.A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80:1996;389-393.
81. Rassam S.M.B., Patel V., Kohner E.M. The effect of acetazolamide on the retinal circulation. Eye. 7:1993;697-702.
82. Ridderstråle Y., Wistrand P.J., Brechue W.F. Membrane-associated CA activity in the eye of the CA II-deficient mouse. Invest. Ophthalmol. Vis. Sci. 35:1994;2577-2584.
83. Rosenberg L.F., Krupin T., Tang L-Q., Hong P.H., Ruderman J.M. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology. 105:1998;88-93.
84. ®: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles; effect on bioavailability of timolol. Int. J. Pharm. 57:1989;163-168.
85. Rusk C., Sharpe E., Laurence J., Polis A., Adamsons I. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Clin. Ther. 20:1998;454-466.
86. Schmidt K., von Rückmann A., Pillunat L.E. Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma. Br. J. Ophthalmol. 82:1998;758-762.
87. Serdahl C.L., Galustian J., Lewis R.A. The effects of apraclonidine on conjunctival oxygen tension. Arch. Ophthalmol. 107:1989;1777-1779.
88. ™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am. J. Ophthalmol. 126:1998;400-408.
89. Simpson A.J., Gray T.B., Ballantyne C. A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study. Aust. N. Z. J. Ophthalmol. 24:1996;39-42.
90. Sly W.S., Hu P.Y. Human carbonic anhydrases and carbonic anhydrase deficiencies. Ann. Rev. Biochem. 64:1995;375-401.
91. Smith G.M., Alexander R.S., Christianson D.W., McKeever B.M., Ponticello G.S., Springer J.P., Randall W.C., Baldwin J.J., Habecker C.N. Positions of His-64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors. Protein Sci. 3:1994;118-125.
92. Sponsel W.E., Harrison J., Elliott W.R., Trigo Y., Kavanagh J., Harris A. Dorzolamide hydrochloride and visual function in normal eyes. Am. J. Ophthalmol. 123:1997;759-766.
93. Stams T., Chen Y., Boriack-Sjodin P.A., Hurt J.D., Liao J., May J.A., Dean T., Laipis P., Silverman D.N., Christianson D.W. Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein Sci. 7:1998;556-563.
94. Strahlman E., Tipping R., Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch. Ophthalmol. 113:1995;1009-1016.
95. Strahlman E., Tipping R., Vogel R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am. J. Ophthalmol. 122:1996;183-194.
96. Strahlman E.R., Vogel R., Tipping R., Clineschmidt C.M. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology. 103:1996;1283-1293.
97. Strohmaier K., Snyder E., DuBiner H., Adamsons I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology. 105:1998;1936-1944.
98. Sugrue M.F. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J. Ocular Pharmacol. Ther. 12:1996;363-376.
99. Sugrue M.F. New approaches to antiglaucoma therapy. J. Med. Chem. 40:1997;2793-2809.
100. Sugrue M.F., O'Neill-Davis L. The effect of cyclooxygenase inhibition on the ocular hypotensive action of topical carbonic anhydrase inhibitors in rabbits. J. Ocular Pharmacol. 7:1991;201-211.
101. Sugrue M.F., Harris A., Adamsons I. Dorzolamide Hydrochloride: a topically active, carbonic anhydrase inhibitor for the treatment of glaucoma. Drugs of Today. 33:1997;283-298.
102. Sugrue M.F., Mallorga P., Schwam H., Baldwin J.J., Ponticello G.S. A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr. Eye Res. 9:1990;607-615.
103. Supuran C.T., Scozzafava A., Saramet I., Banciu M.D. Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with heterocyclic mercaptans, sulfenamides, sulfonamides and their metal complexes. J. Enzyme Inhibition. 13:1998;177-194.
104. Tarkkanen A. Treatment of chronic open-angle glaucoma associated with pseudoexfoliation. Acta Ophthalmol. 43:1965;514-523.
105. Long-term glaucoma treatment with MK-507, dorzolamide, a topical carbonic anhydrase inhibitor. J. Glaucoma. 4:1995;6-10.
106. Tielsch J.M. The epidemiology and control of open angle glaucoma: a population-based perspective. Annu. Rev. Public Health. 17:1996;121-136.
107. Topper J.E., Brubaker R.F. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest. Ophthalmol. Vis. Sci. 26:1985;1315-1319.
108. Vanlandingham B.D., Brubaker R.F. Combined effect of dorzolamide and latanoprost on the rate of aqueous humor flow. Am. J. Ophthalmol. 126:1998;191-196.
109. Vanlandingham B.D., Maus T.L., Brubaker R.F. The effect of dorzolamide on aqueous humor dynamics in normal human subjects during sleep. Ophthalmology. 105:1998;1537-1540.
110. Wang R-F., Serle J.B., Podos S.M., Sugrue M.F. The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys. Arch. Ophthalmol. 108:1990;511-513.
111. Wang R-F., Serle J.B., Podos S.M., Sugrue M.F. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch. Ophthalmol. 109:1991;1297-1299.
112. Wayman L.L., Larsson L-I., Maus T.L., Brubaker R.F. Additive effect of dorzolamide on aqueous humor flow in patients receiving long-term treatment with timolol. Arch. Ophthalmol. 116:1998;1438-1440.
113. Wayman L., Larsson L-I., Maus T., Alm A., Brubaker R. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch. Ophthalmol. 115:1997;1368-1371.
114. Wilkerson M., Cyrlin M., Lippa E.A., Esposito D., Deasy D., Panebianco D., Fazio R., Yablonski M., Shields M.B. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch. Ophthalmol. 111:1993;1343-1350.
115. Williamson T.H., Harris A. Ocular blood flow measurement. Br. J. Ophthalmol. 78:1994;939-945.
116. Wistrand P.J., Schenholm M., Lönnerholm G. Carbonic anhydrase isoenzymes CA I and CA II in the human eye. Invest. Ophthalmol. Vis. Sci. 27:1986;419-428.
117. Wolfensberger T.J., Mahieu I., Jarvis-Evans J., Boulton M., Carter N.D., Nógrádi A., Hollande E., Bird A.C. Membrane-bound carbonic anhydrase in human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 35:1994;3401-3407.
118. Wong B.K., Bruhin P.J., Barrish A., Lin J.H. Nonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction. Drug Metab. Dis. 24:1996;659-663.
119. Wu Q., Delamere N.A., Pierce W. Jr. Membrane-associated carbonic anhydrase in cultured rabbit nonpigmented ciliary epithelium. Invest. Ophthalmol. Vis. Sci. 38:1997;2093-2102.
120. Wu Q., Pierce W.M. Jr, Delamere N.A. Cytoplasmic pH responses to carbonic anhydrase inhibitors in cultured rabbit nonpigmented ciliary epithelium. J. Membrane Biol. 162:1998;31-38.
121. Yamazaki Y., Miyamoto S., Sawa M. Effect of MK-507 on aqueous humor dynamics in normal human eyes. Jpn. J. Ophthalmol. 38:1994;92-96.
122. Zohdy G.A., Rogers Z.A., Lukaris A., Sells M., Roberts-Harry T.J. A comparison of the effectiveness of dorzolamide and acetazolamide in preventing post-operative intraocular pressure rise following phacoemulsification surgery. J. R. Coll. Surg. Edinb. 43:1998;344-346.